Gilead Sciences (NASDAQ:GILD) Price Target Raised to $177.00

Gilead Sciences (NASDAQ:GILD) had its target price raised by stock analysts at Scotiabank from $140.00 to $177.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s price target would suggest a potential upside of 20.22% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Needham & Company LLC raised their target price on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. HSBC lifted their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Twenty-five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $140.08.

Gilead Sciences Stock Performance

GILD stock opened at $147.23 on Wednesday. The firm has a 50 day simple moving average of $128.39 and a 200 day simple moving average of $121.53. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $153.13. The stock has a market cap of $182.67 billion, a P/E ratio of 22.83, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently made changes to their positions in GILD. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. Geode Capital Management LLC increased its holdings in Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $2,617,152,000. Invesco Ltd. raised its position in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after buying an additional 1,618,453 shares during the last quarter. Finally, Amundi grew its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after acquiring an additional 1,614,355 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.